Journal
MABS
Volume 2, Issue 2, Pages 165-175Publisher
TAYLOR & FRANCIS INC
DOI: 10.4161/mabs.2.2.11360
Keywords
VEGF; VEGF receptors; antibodies; cancer therapy
Categories
Funding
- Uniting Against Lung Cancer
- Effie Marie Cain Scholarship in Angiogenesis Research
Ask authors/readers for more resources
Angiogenesis is required in normal physiological processes, but is also involved in tumor growth, progression and metastasis. Vascular endothelial growth factor (VEGF), a primary mediator of angiogenesis in normal physiology and in disease, and other VEGF family members and their receptors provide targets that have been explored extensively for cancer therapy. Small molecule inhibitors and antibody/protein-based strategies that target the VEGF pathway have been studied in multiple types of cancer. This review will focus on VEGF pathway targeting antibodies that are currently being evaluated in pre-clinical and clinical studies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available